FTC lawsuit and novel securities investigation weigh on Hims & Hers, but the news is largely known; fundamentals remain challenged

What happened

On July 29, 2026, Hims & Hers Health (HIMS) shares fell about 14% after the FTC filed a lawsuit alleging deceptive and unlawful privacy, billing, cancellation, and advertising practices; the company's Q2 10-Q, published August 10, already disclosed this complaint and warned it could materially harm operations. The August 18 press release from Hagens Berman is a routine securities-firm investigation notice, not a new regulatory development, and its tone is promotional rather than evidentiary. The master report's bear case assigns a 30% probability to an implied value of $22, driven by FTC remedies raising churn and acquisition costs, while the base case of $30 assumes non-GLP-1 categories limit the damage. Financially, HIMS trades at 41x EV/EBITDA, gross margin fell to 64% from 76%, and net loss was $86.3 million in Q2, leaving little buffer for legal costs or enforced billing changes. The stock has already bounced from the July 29 low of $25 to $28.77 by August 13, suggesting the market partially digested the FTC suit, but the next 90-day filings must show whether subscription practices are legally constrained and whether gross margin stabilizes.

Implication

The lawsuit introduces a binary risk to the subscription model: if remedies force billing transparency and easy cancellation, Hims may lose its frictionless recurring revenue advantage, pushing towards the bear case of $22. Management's Q2 disclosure already warned that the FTC complaint could materially affect operations, but the company has not quantified the potential impact on churn, customer acquisition cost, or margin, so investors should treat the $30 base case as optimistic until proven otherwise. The next two quarterly filings will be pivotal—watch whether monthly revenue per average subscriber holds above $90, gross margin stays at or above 64%, and branded GLP-1 conversion does not collapse under competing LillyDirect self-pay pricing. A settlement or consent decree that limits deceptive practices without breaking the subscription flow could actually reduce long-term legal risk, but any mandate that raises acquisition costs would eat into the already negative net income ($86.3 million loss in Q2). Given the stock's 41.2x EV/EBITDA and $3.3 billion in liabilities, prudent investors should wait for a better entry near $23, or for evidence that the FTC case is contained while gross margin recovers above 66%.

Thesis delta

The news does not alter the fundamental thesis—the FTC complaint was already disclosed in the July 10 10-Q and priced into the July 29 drop—but the Hagens Berman investigation adds near-term headline risk and could delay re-rating until legal exposure is clearer. The thesis remains a WAIT: the stock is not a buy at current multiples, but the bear case probability of 30% may rise if the law firm's probe yields evidence of systemic billing issues beyond the FTC's allegations. We maintain attractive entry at $23 and trim above $34, with a re-assessment window of 3-6 months.